Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of making Caplacizumab available on the NHS as a treatment for acquired thrombotic thrombocytopenic purpura.

The National Institute of Health and Care Excellence (NICE) is developing guidance on Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura. NICE was able to recommend Caplacizumab for routine use on the NHS in its draft guidance. It expects to publish final guidance in December 2020.

NICE’s draft recommendation on the use of Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura is available at the following link:

https://www.nice.org.uk/guidance/gid-ta10361/documents/final-appraisal-determination-document